News | January 07, 2009

Siteman Cancer Center Adds Second TomoTherapy Hi-Art Treatment System

January 8, 2009 - TomoTherapy Inc. said today that Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO., has commenced treating patients on its second TomoTherapy Hi-Art(R) treatment system.

Siteman, a National Cancer Institute (NCI) Comprehensive Cancer Center, installed its first Hi-Art system in early 2006. The installation of a second unit enables more cancer patients to benefit from this intensity-modulated radiation therapy (IMRT) solution.

"We knew the benefits of arc-based radiation delivery before installing our first TomoTherapy unit,” said Dan Low, Ph.D., associate professor of radiation oncology, Washington University School of Medicine. “Upon installation, we gained the ability to deliver IMRT in a continuous helical pattern, and the infrastructure and workflow to apply image guidance to each treatment, for every patient. This is something we cannot do on any other system. As we've become more accustomed to the benefits of this platform, we saw a need for a second Hi-Art system."

For more information: www.TomoTherapy.com, www.siteman.wustl.edu.

Related Content

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System
News | Intensity Modulated Radiation Therapy (IMRT) | October 25, 2017
Varian recently announced an 80-year-old male with head and neck cancer became the first patient in Europe to be...
Varian Receives FDA 510k Clearance for Halcyon Treatment System
Technology | Intensity Modulated Radiation Therapy (IMRT) | July 05, 2017
Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Halcyon system,...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
cervical and endometrial cancer, IMRT, intensity modulated radiation therapy, side effects, ASTRO 2016 study
News | Intensity Modulated Radiation Therapy (IMRT) | September 29, 2016
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience...